RE:RE:RE:Potential Outcomes at 76 patients - wow !I have reviewed MM's projected calculations based on real world numbers his calculations are actually conservative (the multiples on earnings is very conservative as opposed to medical device company comparables) and I agree with AccountPrince in that I would not take anything less than $4:00 a share based on an early buyout of Spectral after the 90 patient data is reviewed by Baxter and the FDA.
I would then hold a large portion of my significant ownership until we reach a true value which I agree with MM to be closer to $9.00 or $10 a share.
I would remind everyone that this will likely be the new standard of care in all ICUs across North America. And Baxter knows it!
GLTA
Rev